Advertisement

Global Vaccine Adjuvant Market Forecasted to Reach USD 6.93 Billion by 2028

Company Logo
Company Logo

Vaccine Adjuvant Market

Vaccine Adjuvant Market
Vaccine Adjuvant Market

Dublin, April 01, 2024 (GLOBE NEWSWIRE) -- The "Vaccine Adjuvant Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class, Type, and Geography" report has been added to ResearchAndMarkets.com's offering.

Growth Trajectory and Market Drivers

Recent studies showcase that the vaccine adjuvant market is on a steep upward trend with expectations to burgeon from US$ 2.482 billion in 2022 to a staggering US$ 6.931 billion by 2028. The sector is set to advance at a Compound Annual Growth Rate (CAGR) of 13.7% from 2022 onwards. A significant element propelling this growth trajectory is the vibrant synergy between adjuvant studies facilitation and concerted product launch efforts.



The Role of Adjuvants in Public Health

Adjuvants are seminal components that augment vaccine effectiveness by amplifying the immune response in vaccine recipients. With a heightened focus on addressing infectious diseases and supporting global health security, the incorporation of adjuvants in vaccines is deemed indispensable. The expansion of the market is further cemented by regulatory endorsements of adjuvants for veterinary applications. Nonetheless, the industry continues to navigate challenges, including product recalls and the management of adverse effects.

Innovation and Regulatory Support

Continued support from entities such as the National Institute of Allergy and Infectious Diseases (NIAID) is a boon for adjuvant innovation and vaccine enhancement. Collaborations and product launches are vital to the sector's robustness, with industry giants actively engaging in strategic partnerships to satisfy global requirements. For instance, a recent application for a novel biological license exhibits the promise and potential within this dynamic market space.

Segmental Insights

The mineral salt adjuvant segment remains dominant within the adjuvant class in the vaccine adjuvant market in 2022, with emulsion adjuvants projected to showcase the fastest growth in the forthcoming years. The efficacy of mineral salt-based adjuvants, particularly those utilizing aluminum salts, in eliciting a rapid immune response highlights their importance in vaccine development.

Regional Landscape and Future Outlook

North America stands at the forefront of the global vaccine adjuvant market, thanks in part to expedited product approval pathways and a robust pharmaceutical infrastructure. The Asia-Pacific region is poised to exhibit the highest growth rate from 2022 to 2030, a testament to the region's emerging potential in the market. Recent FDA approvals of adjuvanted vaccines underscore the market's preparedness to address public health needs effectively.

Strategic Industry Developments

The vaccine adjuvant market is characterized by a series of strategic developments, with industry leaders committing to innovation, collaborations, and market expansion. Partnerships to enhance sustainable adjuvant technologies, coupled with promotions for increased production capabilities, are testimonies to the industry's forward-looking approach.

In response to these advances, stakeholders in the vaccine adjuvant market continue to focus on strategic realignment, market expansion, and the development of long-term, global strategies. End-users are encouraged to stay abreast of market trends, drivers, and constraints to inform decision-making processes and optimize strategic plans.

The vaccine adjuvant market's evolution is indicative of the healthcare sector's resilience and adaptability. With a steadfast commitment to innovation and collaborative strategies, the market is geared towards meeting the demands of an ever-changing global health landscape.

A selection of companies mentioned in this report includes, but is not limited to:

ADVERTISEMENT
  • SPI Pharma Inc

  • GSK Plc

  • CSL Ltd

  • Seppic SA

  • Hawaii Biotech Inc

  • Dynavax Technologies Corp

  • InvivoGen SAS

  • Croda International Plc

  • Novavax Inc

  • Phibro Animal Health Corp


For more information about this report visit https://www.researchandmarkets.com/r/kv32j4

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900